IL-18: a new player in immunotherapy for age-related macular degeneration?. (October 2014)

• Record Type: Journal Article
• Authors: Campbell, Matthew; Doyle, Sarah; Humphries, Peter
• Is Part Of: Expert review of clinical immunology. Volume 10:Number 10(2014)
• Page Start: 1273
• Page End: 1275
• Publication Date: 2014-10
• Subjects: Clinical immunology -- Periodicals; 616.079
• DOI: 10.1586/1744666X.2014.950231
• Languages: English
• ISSNs: 1744-666X

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>Recent evidence suggests that the pro-inflammatory cytokine IL-18 may have utility as an anti-angiogenic agent in the eye. Numerous laboratories, including our own have demonstrated the ability of murine IL-18 to prevent neovascularization in the retina, choroid and cornea in pathological scenarios. Here, we summarize the potential use of IL-18 as an immunotherapy for wet age-related macular degeneration treatment, describing past and recent findings pertaining to its biological function in the eye.</p> </abstract>